Rheumatoid arthritis (RA) weight new drug! Rinvoq, an oral Jak1 inhibitor, is the third regulatory approval in the world, with an annual sales volume of $2.6 billion

January 9, 2020 / BIOON / -- American biopharmaceutical giant abbvie recently announced that Health Canada has approved rinvoq (upadacitinib), a Jak1 inhibitor, for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA) who have insufficient or intolerant response to methotrexate (MTX) The drug is a selective and reversible JAK inhibitor, which can be used as a single drug therapy or in combination with MTX or other non biological disease modified anti rheumatic drugs (DMARD) In August 2019, rinvoq won the first batch in the world in the United States At present, the drug has been listed in the United States One tablet (15mg) is taken orally once a day The drug is not suitable for patients who have not received MTX treatment It is worth mentioning that Albright accelerated rinvoq's review in the US FDA by using a priority review voucher (PRV) In December 2019, rinvoq was approved by the European Union for the treatment of adult patients with moderate to severe RA who have insufficient or intolerable response to one or more dmars "Although great progress has been made in the treatment of rheumatoid arthritis in the past 20 years, there are still too many patients who cannot be relieved and continue to suffer from pain, fatigue and morning stiffness," said Edward keystone, M.D., a professor of medicine at the University of Toronto Rinvoq is supported by one of the largest phase III clinical trials in the field of rheumatoid arthritis and has the potential to significantly improve the symptoms and signs of the disease " St é phane lassignardie, vice chairman and general manager of Aberdeen Canada, said: "for nearly 20 years, Aberdeen has been committed to finding and providing innovative therapies for patients with rheumatic diseases We are proud to provide a new treatment for rheumatoid arthritis patients in Canada Rinvoq is a sustained-release tablet taken once a day, which is convenient for oral administration " Rinvoq has been approved in the United States, the European Union and Canada, all based on the data of Global Select III RA project The project is one of the largest registered phase III projects in the field of RA, including 5 phase III studies, involving more than 4400 RA patients These studies evaluated rinvoq's efficacy, safety, and tolerability in a wide range of RA patients, including those who failed or were intolerant to the use of biologically modified antirheumatic drugs, those who did not receive methotrexate (MTX), or those who did not respond adequately to MTX In all studies, rinvoq reached the primary and secondary end points of the study: as a single drug therapy and combined with traditional synthetic DMARD, it improved the symptoms and signs of RA, inhibited the progress of Radiology, and improved the body function In terms of safety, the most common serious adverse event was infection The top line data of these studies have been published before, and the main end point data are as follows: - select early study: in patients who have not received MTX, 52% of patients in rinvoq 15mg treatment group achieved acr50 remission in the 12th week of treatment, and 28% in MTX treatment group ——Select monotherapy study: in mtx-ir patients, at the 14th week of treatment, 68% of patients in rinvoq 15mg treatment group achieved ACR20 remission, and 41% of patients continued to receive MTX treatment ——Select compare study: in mtx-ir patients, 71% of the patients in rinvoq 15mg + MTX group achieved ACR20 remission in the 12th week, while 36% in placebo + MTX group ——Select-next study: it was carried out in patients with insufficient or intolerant response to traditional synthetic disease modified antirheumatic drugs (csdmard-ir) The treatment group was 12 weeks lower, and 64% of patients in rinvoq 15mg + csdmard treatment group achieved ACR20 remission, while 36% in placebo + csdmard treatment group ——Select beyond study: it was carried out in patients with inadequate or intolerant biological IR response At the 12th week of treatment, 65% of patients in rinvoq 15mg + csdmard treatment group achieved ACR20 remission, while 28% in placebo + csdmard treatment group Rinvoq's active drug ingredient is upadacitinib, an oral selective Jak1 inhibitor discovered and developed by Aberdeen, which is being developed to treat moderate to severe RA and other immune-mediated diseases Jak1 is a kinase that plays a key role in the pathophysiological process of various inflammatory diseases At present, the phase III clinical study of upadacitinib in the treatment of psoriatic arthritis (PSA), Crohn's disease (CD), atopic dermatitis (AD), ulcerative colitis (UC), giant cell arteritis is in progress In addition, upadacitinib is also being evaluated for the treatment of ankylosing spondylitis The industry is very optimistic about rinvoq's business prospects According to a previous report released by evaluatepharma, a pharmaceutical market research organization, rinvoq's global sales will reach US $2.57 billion in 2024, making it the fifth largest selling anti rheumatic drug in the world Original source: abbvie receives Health Canada approval of rinvoq ® (upadacitinib), an oral mediation for the treatment of results with moderate to severe active rheumatoid arts Fran ç AIS